Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 1

Cancer-Associated Retinopathy and Its Clinical Features

Kanser İlişkili Retinopati ve Klinik Özellikleri

Pages
69–72
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Unfortunately, she died in three months time due to multiple metastasis.Conclusion: Cancer-associated retinopathy should be considered in differential diagnosis of patients presenting with progressive vision loss and nyctalopia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To report the clinical features of a case with cancer-related retinopathy and review the disease.Method: Retrospective case report.Results: A 65-year-old woman was presented to us with a history of bilateral gradual vision deterioration and nyctalopia for three months'duration.
📊
Key Findings & Data:She was previously diagnosed to have a neuroendocrine tumor in 2008 and received a multitude of systemic therapies including surgical resection, chemotherapy and radiotherapy.
💡
Conclusion & Impact:Unfortunately, she died in three months time due to multiple metastasis.Conclusion: Cancer-associated retinopathy should be considered in differential diagnosis of patients presenting with progressive vision loss and nyctalopia.
🔬Design:Review & Systematic Survey
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To report the clinical features of a case with cancer-related retinopathy and review the disease.Method: Retrospective case report.Results: A 65-year-old woman was presented to us with a history of bilateral gradual vision deterioration and nyctalopia for three months'duration. She was previously diagnosed to have a neuroendocrine tumor in 2008 and received a multitude of systemic therapies including surgical resection, chemotherapy and radiotherapy. On examination, her best-corrected visual acuity was 0.3 with normal anterior segment and normal looking posterior pole OU. Bilateral peripheral consantric narrowing was present at the visual field test and depressed scotopic responses was revealed at the ERG test. The diagnosis was cancer-associated retinopathy. Unfortunately, she died in three months time due to multiple metastasis.Conclusion: Cancer-associated retinopathy should be considered in differential diagnosis of patients presenting with progressive vision loss and nyctalopia.

Özet

AMAÇ: Kanser ilişkili retinopatili bir hastanın klinik özelliklerinin sunularak hastalığın gözden geçirilmesiMetod: Retrospektif olgu sunumuBulgular: Altmışbeş yaşında kadın hasta özellikle son üç ayda her iki gözde ilerleyici az görme ve gece görememe şikayeti ile kliniğimize başvurdu. Hastanın özgeçmişinde 2008 yılında nöroendokrin tümör tanısı ile cerrahi rezeksiyon, kemoterapi ve radyoterapi gibi tedaviler aldığı önerildi. Muayenesinde her iki gözde en iyi düzeltilmiş görme keskinliği 0.3 ölçüldü. Ön segment ve fundus muayenelerinde belirgin patoloji saptanmayan hastanın görme alanında bilateral periferik konsantrik daralma ile elektroretinografik değerlendirmesinde skotopik yanıtlarda azalma olduğu görüldü. Hastada kanser ilişkili retinopati tanısı konuldu. Hasta uzak organ metastazları nedeniyle 3 ay sonra hayatını kabettiSonuç: Kanser ilişkili retinopati görme keskinliğinde azalma ve bazen de gece körlüğü yakınmalarıyla karakterize bir antite olduğu için böyle yakınmaları olan hastalarda ayırıcı tanıda mutlaka düşünülmelidir.

🔖

Cite This Article

AYHAN, Z., ÜNLÜ, B., SEYMENOĞLU, G., SAATCİ, A. O. (2017). Cancer-Associated Retinopathy and Its Clinical Features. Retina-Vitreus, Cilt: 26 - Sayı: 1, 69–72. https://ajindex.com/articles/304938

References (16)

  1. Arnold AC, Lee AG. Systemic disease and neuro-ophthalmology: annual update 2000. J Neuroophthalmol 2001;21:46-61
  2. Sawyer RA, Selhorst JB, Zimmerman LE, et al. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmology 1976;181:606-13
  3. Chan JW. Paraneoplastic retinopathies and optic neuropathies. Survey Ophthalmol 2003;48:12-38
  4. Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy. Arch Ophthalmol 1987;105:372-75
  5. Sampedro A, Carballo C, Barbón JJ, et al. Ocular paraneoplastic syndrome: cancer-associated retinopathy. Arch Soc Esp Oftalmol. 2013;88:407-9
  6. Makiyama Y, Kikuchi T, Otani A, et al. Clinical and immunological characterization of paraneoplastic retinopathy. Invest Ophthalmol Vis Sci. 2013;54:5424-31
  7. Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 1990;28:162-7
  8. Hooks JJ, Tso MO, Detrick B. Retinopathies associated with anti-retinal antibodies. Clin Diagn Lab Immunol 2001:8;853-58
  9. Thirkill CE, Tait RC, Tyler NK. The Cancer-Associated Retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci 1992;33:2768-72
  10. Ohguro H, Ogawa K, Maeda T, et al. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthmol Vis Sci 1999;40:3160-67
  11. Whitcup SM, Vistica BP, Milam AH, et al. Recoverin-associated retinopathy: a clinical and immunologically distinctive disease. Am J Ophthalmol 1998;126:230-7
  12. Adamus G, Choi D, Raghunath A, et al. Significance of Anti-retinal Autoantibodies in Cancer-associated Retinopathy with Gynecological Cancers. J Clin Exp Ophthalmol. 2013;4:307 13. Eltabbakh GH, Hoogerland DL, Kay MC. Paraneoplastic retinopathy associated with uterine sarcoma. Gynecol Oncol 1995;58:120- 3
  13. Keltner JL, Thirkill CE, Tyler NK, et al. Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol 1992;110:48-53
  14. Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 1999;117:471-7
  15. Murphy MA, Thirkill CE, Hart WM Jr. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol 1997;17:77-83
  16. Or C, Collins DR, Merkur AB, et al. Intravenous rituximab for the treatment of cancer-associated retinopathy. Can J Ophthalmol. 2013;48:35-8.